• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

    10/15/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TWST alert in real time by email

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/

    Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire)

    Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire)

    "Mike's extensive background in building and configuring scalable enterprise software platforms, paired with a deep understanding of systems biology and artificial intelligence and importantly, his experience as a Twist customer, uniquely positions him to understand and drive our mission to enable our customers to improve health and sustainability by delivering DNA at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "I am confident his leadership will play a pivotal role in reinforcing Twist's technology infrastructure and accelerating product execution efficiency to support our growing product portfolio and expanding customer base."

    "My technical expertise along with my extensive hands-on experience as a salesman, marketer and lab worker as well as a customer of Twist, gives me a comprehensive understanding of the evolving needs of our customers and employees," commented Dr. Fero. "Since joining Twist as a consultant in March, I've gained valuable insights into our internal workflows and how to optimize our systems to best serve our customers, allowing us to scale significantly by leveraging technology. As I step into this new position, I am excited to continue partnering with our talented Twist teams and am committed to increasing system efficiency, reliability and consistently elevating the experiences of all stakeholders."

    Before joining Twist, Dr. Fero co-founded and served as CEO of TeselaGen Biotechnology for a decade, where he spearheaded TeselaGen's enterprise software platform, providing a comprehensive suite of tools for DNA design, assembly, management and experimental workflows to a range of biotech customers from startups to Fortune 50 companies. Prior to TeselaGen, he was a principal investigator and NIH Career Fellow at Stanford University where he explored the signaling pathways that govern the bacteria cell cycle through the development of an automated epifluorescence microscopy platform including both hardware and software for high-throughput, high-content genetic screens and subsequent data analysis. He also served as director of Stanford Functional Genomics, where he collaborated on the development of the first human and murine genome scale microarrays. Prior to Stanford, Dr. Fero served as vice president of software engineering at Neomorphic where he guided development of a laboratory information management system (LIMS) solution for the human genome project at Lawrence Berkeley National Laboratory. Before Neomorphic, he held a variety of escalating positions at HyperParallel and Massachusetts Institute of Technology.

    Dr. Fero holds a Ph.D. in Physics and a B. A. in both Math and Physics, both from the University of California, Irvine. He completed a postdoctoral fellowship at the Massachusetts Institute of Technology, Cambridge and conducted international studies in Maths at Trinity College, Dublin. Dr. Fero serves as an advisor to both government and private groups exploring the promise, limits and concerns around the field of synthetic biology.

    About Twist Bioscience Corporation

    Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

    Follow us on LinkedIn | X | YouTube | Instagram

    Twist Bioscience Legal Notice Regarding Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience's restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241008118663/en/

    Get the next $TWST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TWST

    DatePrice TargetRatingAnalyst
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    2/7/2022$130.00 → $75.00Overweight
    Barclays
    More analyst ratings

    $TWST
    Financials

    Live finance-specific insights

    See more
    • Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f

      5/5/25 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Spins Out DNA Data Storage as Independent Company

      Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage Twist remains focused on serving customers across the life sciences spectrum and expanding rev

      5/5/25 7:10:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025

      Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor

      4/14/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      11/8/24 2:38:08 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Twist Bioscience Corporation

      SC 13G - Twist Bioscience Corp (0001581280) (Subject)

      11/8/24 9:39:34 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

      SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      11/5/24 6:07:26 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Twist Bioscience with a new price target

      Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

      12/13/24 8:32:53 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Twist Bioscience with a new price target

      Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00

      6/4/24 7:44:10 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience upgraded by Goldman with a new price target

      Goldman upgraded Twist Bioscience from Neutral to Buy and set a new price target of $45.00 from $25.00 previously

      1/17/24 7:47:50 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

      For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

      3/26/21 3:51:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    Leadership Updates

    Live Leadership Updates

    See more
    • Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

      10/15/24 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him

      1/5/24 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Appoints Mark Buck as Senior Vice President, Operations

      Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mark Buck as senior vice president, operations. Mr. Buck brings experience improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics. "Building on the foundation of his time serving in the United State Marine Corps and drawing from military efficiency, Mark has established a career in industry developing and optimizing operational processes and requirements that enable scale for multiple

      10/3/23 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Twist Bioscience and Ginkgo Bioworks Revise Collaboration

      New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15

      5/8/25 8:00:00 AM ET
      $DNA
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f

      5/5/25 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Spins Out DNA Data Storage as Independent Company

      Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage Twist remains focused on serving customers across the life sciences spectrum and expanding rev

      5/5/25 7:10:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    SEC Filings

    See more
    • SEC Form 10-Q filed by Twist Bioscience Corporation

      10-Q - Twist Bioscience Corp (0001581280) (Filer)

      5/5/25 4:05:23 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Twist Bioscience Corp (0001581280) (Filer)

      5/5/25 7:27:31 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

      SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      4/17/25 9:35:32 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Cho Dennis sold $163,590 worth of shares (5,000 units at $32.72), decreasing direct ownership by 5% to 105,849 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/9/25 4:05:06 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and COO Finn Patrick John sold $105,423 worth of shares (2,800 units at $37.65), decreasing direct ownership by 1% to 262,660 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/7/25 4:05:18 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Cho Dennis sold $25,942 worth of shares (689 units at $37.65), decreasing direct ownership by 0.62% to 110,849 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/7/25 4:05:21 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care